Robert Wong Net Worth

The estimated Net Worth of Robert Wong is at least $1.85 millió dollars as of 3 June 2024. Mr. Wong owns over 13,011 units of Cytokinetics Inc stock worth over $895,432 and over the last 5 years he sold CYTK stock worth over $957,585. In addition, he makes $0 as Chief Accounting Officer és Vice President at Cytokinetics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Wong CYTK stock SEC Form 4 insiders trading

Robert has made over 4 trades of the Cytokinetics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 13,011 units of CYTK stock worth $635,978 on 3 June 2024.

The largest trade he's ever made was selling 13,011 units of Cytokinetics Inc stock on 3 June 2024 worth over $635,978. On average, Robert trades about 1,272 units every 35 days since 2020. As of 3 June 2024 he still owns at least 16,653 units of Cytokinetics Inc stock.

You can see the complete history of Mr. Wong stock trades at the bottom of the page.

Robert Wong biography

Robert C. Wong serves as Chief Accounting Officer, Vice President of the Company. Prior to joining Cytokinetics, Robert was at Genentech for over 23 years with roles of increasing responsibility in accounting, reporting, and internal controls, most recently as Interim Controller and Chief Accounting Officer. He has extensive experience in accounting for mergers, acquisitions and business development collaborations, reporting under US and International accounting standards, and complying with internal control regulations. Prior to Genentech, Robert was an Audit Manager at Ernst & Young LLP for over seven years. Robert received his B.S. in Business Administration, Accounting & Finance from the University of California, Berkeley and is a certified public accountant. A native San Franciscan, Robert enjoys his spare time working on a house or car repair project and spending time with his wife and three kids during their school and dance activities.

How old is Robert Wong?

Robert Wong is 52, he's been the Chief Accounting Officer és Vice President of Cytokinetics Inc since 2019. There are 20 older and no younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.

What's Robert Wong's mailing address?

Robert's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.

Insiders trading at Cytokinetics Inc

Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi... és Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.

What does Cytokinetics Inc do?

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Complete history of Mr. Wong stock trades at Cytokinetics Inc

Cytokinetics Inc executives and stock owners

Cytokinetics Inc executives and other stock owners filed with the SEC include:

• Robert Blum,
  President, Chief Executive Officer, Director
• Fady Malik,
  Executive Vice President - Research and Development
• Mark Schlossberg,
  Senior Vice President, General Counsel, Secretary
• Ching Jaw,
  Chief Financial Officer, Senior Vice President
• David Cragg,
  Chief Human Resource Officer, Chief Administrative Officer
• Robert I. Blum,
  CEO, Pres & Director
• Dr. Fady Ibraham Malik,
  Exec. VP of R&D
• Mark A. Schlossberg,
  Sr. VP of Legal, Gen. Counsel & Sec.
• Ching W. Jaw,
  Sr. VP & CFO
• David W. Cragg,
  Chief HR & Admin. Officer
• Leonard Patrick Gage,
  Independent Chairman of the Board
• Wendall Wierenga,
  Independent Director
• B. Lynne Parshall,
  Independent Director
• John Henderson,
  Independent Director
• Santo Costa,
  Independent Director
• Sandford Smith,
  Independent Director
• Edward Kaye,
  Independent Director
• Robert Califf,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Diane Weiser,
  IR Contact Officer
• Robert Wong,
  Chief Accounting Officer, Vice President
• Kari K. Loeser J.D.,
  VP & Chief Compliance Officer
• Robert Wong,
  VP & Chief Accounting Officer
• Jeff Lotz,
  VP of Sales & Operations
• Dr. James A. Spudich Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Bradley Paul Morgan,
  SVP Drug Discovery & Early Dev
• Caryn Gordon Mc Dowell,
  GC & Chief Compliance Officer
• Elisabeth Schnieders,
  Sr. VP, Business Development
• L Patrick Gage,
  Director
• Bonnie Charpentier,
  SVP Regulatory & Compliance
• Robert Arthur Harrington,
  Director
• Associates Vi Lp Srb,
  10% owner
• Sung Lee,
  EVP, Chief Financial Officer
• Peter S Roddy,
  SVP Finance & CAO
• Muna Bhanji,
  Director
• Michael Rabson,
  SVP Business Dev/Legal & GC
• A Grant Iii Heidrich,
  Director
• Mark Mcdade,
  Director
• Brett A Pletcher,
  EVP, Chief Legal Officer
• Sharon Barbari,
  Sr. VP, Finance & CFO
• Charles J Homcy,
  Director
• James H Sabry,
  President and CEO
• David J Jr Morgans,
  SVP-Drug Discovery and Dev
• James A Spudich,
  Director
• Michael Schmertzler,
  Director
• Jay K Trautman,
  VP, Technology
• Stephen M Dow,
  Director
• Denise Gilbert,
  Director
• Capital Ltd Portfolio Servi...,
  
• Suisse First Boston/Credit ...,
  
• John Vdomenik Stephen Lbayl...,
  
• William J Rutter,
  Director
• Ixmayfield Ix Management Ll...,
  
• Rosen Vii Affiliates Fund L...,
  10% owner
• Associates Vii Lp Srb,
  10% owner
• Associates Viii Lp Srb,
  10% owner
• Rosen Viii Affiliates Fund ...,
  10% owner
• Rosen Fund Viii Lp Sevin,
  10% owner
• Rosen Fund Vi Lp Sevin,
  10% owner
• Rosen Fund Vii Lp Sevin,
  10% owner
• Rosen Vi Affiliates Fund Lp...,
  10% owner
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Andrew Callos,
  EVP, Chief Commercial Officer